Drugs / MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine
MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00373217 | Apr 2006 → Feb 2008 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Craig L Slingluff, Jr | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00373217 ↗ |
| Action | Deplete | “Vaccines made from peptides may help the body build an effective immune response to kill tumor cells.” NCT00373217 ↗ |
| Modality | Vaccine | “vaccine therapy comprising synthetic ovarian cancer-associated peptides” NCT00373217 ↗ |
| Route | Subcutaneous | “Given intradermally or subcutaneously” NCT00373217 ↗ |